Cargando…
Surface-modified gatifloxacin nanoparticles with potential for treating central nervous system tuberculosis
A new nanocarrier is developed for the passage of gatifloxacin through the blood–brain barrier to treat central nervous system tuberculosis. Gatifloxacin nanoparticles were prepared by nanoprecipitation using poly(lactic-co-glycolic acid) (PLGA) 502 and polysorbate 80 or Labrafil as surface modifier...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357078/ https://www.ncbi.nlm.nih.gov/pubmed/28331318 http://dx.doi.org/10.2147/IJN.S130908 |
_version_ | 1782515980526682112 |
---|---|
author | Marcianes, Patricia Negro, Sofia García-García, Luis Montejo, Consuelo Barcia, Emilia Fernández-Carballido, Ana |
author_facet | Marcianes, Patricia Negro, Sofia García-García, Luis Montejo, Consuelo Barcia, Emilia Fernández-Carballido, Ana |
author_sort | Marcianes, Patricia |
collection | PubMed |
description | A new nanocarrier is developed for the passage of gatifloxacin through the blood–brain barrier to treat central nervous system tuberculosis. Gatifloxacin nanoparticles were prepared by nanoprecipitation using poly(lactic-co-glycolic acid) (PLGA) 502 and polysorbate 80 or Labrafil as surface modifiers. The evaluation of in vivo blood–brain barrier transport was carried out in male Wistar rats using rhodamine-loaded PLGA nanoparticles prepared with and without the surface modifiers. At 30 and 60 minutes after administration, nanoparticle biodistribution into the brain (hippocampus and cortex), lungs, and liver was studied. The results obtained from the cerebral cortex and hippocampus showed that functionalization of rhodamine nanoparticles significantly increased their passage into the central nervous system. At 60 minutes, rhodamine concentrations decreased in both the lungs and the liver but were still high in the cerebral cortex. To distinguish the effect between the surfactants, gatifloxacin-loaded PLGA nanoparticles were prepared. The best results corresponded to the formulation prepared with polysorbate 80 with regard to encapsulation efficiency (28.2%), particle size (176.5 nm), and ζ-potential (−20.1 mV), thereby resulting in a promising drug delivery system to treat cerebral tuberculosis. |
format | Online Article Text |
id | pubmed-5357078 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-53570782017-03-22 Surface-modified gatifloxacin nanoparticles with potential for treating central nervous system tuberculosis Marcianes, Patricia Negro, Sofia García-García, Luis Montejo, Consuelo Barcia, Emilia Fernández-Carballido, Ana Int J Nanomedicine Original Research A new nanocarrier is developed for the passage of gatifloxacin through the blood–brain barrier to treat central nervous system tuberculosis. Gatifloxacin nanoparticles were prepared by nanoprecipitation using poly(lactic-co-glycolic acid) (PLGA) 502 and polysorbate 80 or Labrafil as surface modifiers. The evaluation of in vivo blood–brain barrier transport was carried out in male Wistar rats using rhodamine-loaded PLGA nanoparticles prepared with and without the surface modifiers. At 30 and 60 minutes after administration, nanoparticle biodistribution into the brain (hippocampus and cortex), lungs, and liver was studied. The results obtained from the cerebral cortex and hippocampus showed that functionalization of rhodamine nanoparticles significantly increased their passage into the central nervous system. At 60 minutes, rhodamine concentrations decreased in both the lungs and the liver but were still high in the cerebral cortex. To distinguish the effect between the surfactants, gatifloxacin-loaded PLGA nanoparticles were prepared. The best results corresponded to the formulation prepared with polysorbate 80 with regard to encapsulation efficiency (28.2%), particle size (176.5 nm), and ζ-potential (−20.1 mV), thereby resulting in a promising drug delivery system to treat cerebral tuberculosis. Dove Medical Press 2017-03-13 /pmc/articles/PMC5357078/ /pubmed/28331318 http://dx.doi.org/10.2147/IJN.S130908 Text en © 2017 Marcianes et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Marcianes, Patricia Negro, Sofia García-García, Luis Montejo, Consuelo Barcia, Emilia Fernández-Carballido, Ana Surface-modified gatifloxacin nanoparticles with potential for treating central nervous system tuberculosis |
title | Surface-modified gatifloxacin nanoparticles with potential for treating central nervous system tuberculosis |
title_full | Surface-modified gatifloxacin nanoparticles with potential for treating central nervous system tuberculosis |
title_fullStr | Surface-modified gatifloxacin nanoparticles with potential for treating central nervous system tuberculosis |
title_full_unstemmed | Surface-modified gatifloxacin nanoparticles with potential for treating central nervous system tuberculosis |
title_short | Surface-modified gatifloxacin nanoparticles with potential for treating central nervous system tuberculosis |
title_sort | surface-modified gatifloxacin nanoparticles with potential for treating central nervous system tuberculosis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357078/ https://www.ncbi.nlm.nih.gov/pubmed/28331318 http://dx.doi.org/10.2147/IJN.S130908 |
work_keys_str_mv | AT marcianespatricia surfacemodifiedgatifloxacinnanoparticleswithpotentialfortreatingcentralnervoussystemtuberculosis AT negrosofia surfacemodifiedgatifloxacinnanoparticleswithpotentialfortreatingcentralnervoussystemtuberculosis AT garciagarcialuis surfacemodifiedgatifloxacinnanoparticleswithpotentialfortreatingcentralnervoussystemtuberculosis AT montejoconsuelo surfacemodifiedgatifloxacinnanoparticleswithpotentialfortreatingcentralnervoussystemtuberculosis AT barciaemilia surfacemodifiedgatifloxacinnanoparticleswithpotentialfortreatingcentralnervoussystemtuberculosis AT fernandezcarballidoana surfacemodifiedgatifloxacinnanoparticleswithpotentialfortreatingcentralnervoussystemtuberculosis |